leadf
logo-loader
viewScancell Holdings PLC

Scancell Holdings PLC: Proactive One2One Virtual Conference

Scancell Holdings PLC's (LON:SCLP) Dr Cliff Holloway presents at the Proactive One2One Virtual Conference. The company's lead drug, SCIB-1, developed from its ImmunoBody technology, has recently entered a phase II clinical trial in the UK. The study will initially assess the safety and efficacy of the treatment in 25 people with a metastatic form of skin cancer, melanoma. SCIB-1 will be used in harness with Merck’s checkpoint inhibitor Keytruda.

Quick facts: Scancell Holdings PLC

Price: 14.3 GBX

LSE:SCLP
Market: LSE
Market Cap: £103.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: UK awaits Westminsters' three-tier local lockdown system

FTSE 100 opened lower as it nervously awaits Westminster’s announcement on the three-tier local lockdown system scheduled for today. British Airways is replacing chief executive Alex Cruz with Aer Lingus boss Sean Doyle. Cruz was criticised by politicians and trade unions after cutting 10,700...

1 week, 1 day ago

2 min read